BioCardia, Inc. (BCDA) earnings
BCDA earnings moved a median of -4.54% by the close. Quarterly and annual BCDA reports and results, each read against the price at its own news timestamp. Back to the BCDA overview →
22 measured BCDA earnings events.
Where these BCDA earnings landedvs 20 measured BCDA earnings reactions
| Middle 50% of BCDA earnings reactions | -8.18% to +1.70% |
|---|---|
| Median reaction (to close) | -4.54% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 BCDA earnings events with a measured close landed between -8.18% and +1.70%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results | Press release | +3.53% | +5.56% | |
| Form 10-Q BioCardia, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.53% | +5.56% | |
| BioCardia Reports First Quarter 2026 Business Highlights and Financial Results | Press release | -1.81% | -8.18% | |
| Form 10-Q BioCardia, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.81% | -8.18% | |
| Form 10-K BioCardia, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.00% | |
| BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results | Press release | +0.00% | — | |
| Form 10-Q BioCardia, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Form 10-Q/A BioCardia, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.85% | -3.08% | |
| BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results | Press release | -1.99% | -4.54% | |
| Form 10-Q BioCardia, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.99% | -4.54% | |
| BioCardia Reports First Quarter 2025 Business Highlights and Financial Results | Press release | +6.04% | -15.33% | |
| Form 10-Q BioCardia, Inc. For: Mar 31 | SEC filing · Form 10-Q | +6.04% | -15.33% | |
| Form 10-K BioCardia, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.54% | +1.13% | |
| BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results | Press release | +2.32% | -12.01% | |
| Form 10-Q BioCardia, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.32% | -12.01% | |
| BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results | Press release | -1.40% | -5.82% | |
| Form 10-Q BioCardia, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | +3.13% | |
| BioCardia Reports First Quarter 2024 Business Highlights and Financial Results | Press release | -0.76% | +1.70% | |
| Form 10-Q BioCardia, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.76% | +1.70% | |
| Form 10-K BioCardia, Inc. For: Dec 31 | SEC filing · Form 10-K | +5.10% | +4.36% | |
| BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results | Press release | -3.19% | -5.68% | |
| Form 10-Q BioCardia, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.19% | -5.68% |
Keep exploring
More BCDA: analyst actions → · SEC filings → · BCDA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AQUINOX PHARMACEUTICALS (AQXP) | 357 | 0.00% | 46% |
| Hologic, Inc. (HOLX) | 357 | -0.00% | 44% |
| BioMarin Pharmaceutical Inc. (BMRN) | 356 | -0.08% | 45% |
| McKesson Corporation (MCK) | 355 | +0.02% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.